Based at Karolinska Institute Science Park, Stockholm Sweden
Production site AUXESIS PHARMA HOLDING AB (publ) continues its “journey” by visiting the Business Office in Östersund Municipality on Friday 2023-10-27. In addition, Region Jämtland/Härjedalen…
AUXESIS PHARMA HOLDING AB (publ) is now a settlement company and started with Euroclear as the securities institution and Avanza Bank as the company’s Issuance…
Östersund AUXESIS PHARMA HOLDING AB (publ) is in the establishment phase of pharmaceutical manufacturing in Östersund, Sweden. In September 2023 the company will submit an…
Production site AUXESIS PHARMA HOLDING AB (publ) continues its “journey” by visiting the Business Office in Östersund Municipality on Friday 2023-10-27. In addition, Region Jämtland/Härjedalen…
AUXESIS PHARMA HOLDING AB (publ) is now a settlement company and started with Euroclear as the securities institution and Avanza Bank as the company’s Issuance…
Östersund AUXESIS PHARMA HOLDING AB (publ) is in the establishment phase of pharmaceutical manufacturing in Östersund, Sweden. In September 2023 the company will submit an…
Our Team
AUXESIS PHARMA HOLDING AB (publ), is a pharmaceutical company, based in Stockholm, Sweden. The team is interdisciplinary in the medical industry including a Certified Drug Consultant, Professor of Pharmacotherapy, Clinical Pharmacology and Sales and Marketing expertise. Auxesis Pharma Holding AB is a company that owns the rights of any additional and necessary patents in a specific medical research area.
Our product line
Our product line are designed for the global market. The company is working with the FDA for a second introduction to the US market, and are negotiating with strategic pharmaceutical companies for manufacturing and distribution. The active substances of our products has already been approved by the Medical Products Agency in Sweden, which will simplify the process for approval both domestically and globally.
Product in focus
ASA.P® is a non-prescription topical pain elimination drug that can be applied to the skin in different forms. The global challenge today is quick pain relief for topical exposure and infections from sun burn, wasp/ mosquito bites, herpes, nettle, jelly fish etc. Our research reveals that it drastically deminishes pain caused by insect bites, poison plants, rashes, eczema, herpes etc in its own, unique way.
Investor Hub
News and updates from Auxesis Pharma for the Investor Hub exclusively. Documentation available for download.
Partners
+46 (0)8-771 43 00
Copyright All rights reserved AUXESIS PHARMA HOLDING AB (publ) 2023